AUSTIN, Texas, Feb. 6, 2024 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and wholly owned subsidiary of Centene Corporation (NYSE: CNC), today announced it has been named a Best Place for Working Parents® for a fourth consecutive year. This designation is supported by Early Matters Greater Austin, a joint initiative from United Way for Greater Austin and E3 Alliance.
"Supporting working parents with family-friendly policies, benefits, and resources continues to be a priority for our organization," said Superior HealthPlan president and CEO, Mark Sanders. "This designation represents our commitment to that approach, one that I believe allows us to elevate our ability to provide quality healthcare to the nearly two million people we serve across Texas."
Superior was recognized in 2019 as a Family-Friendly Workplace, one of the first 30 organizations in Austin to receive the honor. Ever since, Superior has been named a Best Place for Working Parents®, adding multiple benefits aimed at further supporting employees:
To learn more, visit https://bestplace4workingparents.com/.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality health care throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,200 employees throughout the state. Superior is a wholly owned subsidiary of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. More information on Superior can be found at www.SuperiorHealthPlan.com.
Last Trade: | US$60.70 |
Daily Change: | -1.28 -2.07 |
Daily Volume: | 5,650,442 |
Market Cap: | US$30.650B |
February 24, 2025 February 04, 2025 October 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load